PMID- 38004320
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231128
IS  - 2075-1729 (Print)
IS  - 2075-1729 (Electronic)
IS  - 2075-1729 (Linking)
VI  - 13
IP  - 11
DP  - 2023 Nov 8
TI  - The Therapeutic Potential of Amphetamine-like Psychostimulants.
LID - 10.3390/life13112180 [doi]
LID - 2180
AB  - This review delves into the therapeutic applications of amphetamine-type 
      stimulants such as lisdexamphetamine dimesylate, mixed amphetamine salts, 
      3,4-methylenedioxymethamphetamine (MDMA), dextroamphetamine, and phentermine. 
      These compounds have been investigated for their potential in treating a range of 
      psychiatric disorders, including attention deficit hyperactivity disorder (ADHD), 
      drug dependence, post-traumatic stress disorder (PTSD), and obesity. 
      Lisdexamphetamine dimesylate has shown promise in effectively treating ADHD 
      symptoms in both children and adults. Additionally, it has been explored as a 
      potential treatment for drug dependency and withdrawal, demonstrating encouraging 
      results. Mixed amphetamine salts have also exhibited efficacy in reducing ADHD 
      symptoms in adults. Future research should explore their potential use in 
      treating bipolar disorder and cocaine dependence, considering the associated 
      risks and benefits. MDMA-assisted psychotherapy has emerged as an innovative 
      approach to treating PTSD, leading to sustained reductions in symptoms and even 
      promoting post-traumatic growth. Furthermore, it has shown promise in managing 
      anxiety related to life-threatening illnesses. Dextroamphetamine and phentermine 
      have demonstrated efficacy in treating cocaine and opioid dependence, ADHD, and 
      obesity. However, careful consideration and monitoring by medical professionals 
      are essential due to the potential risks and benefits associated with them. In 
      conclusion, amphetamine-type stimulants present a promising avenue for 
      therapeutic interventions in various psychiatric conditions. Nevertheless, 
      further research is necessary to comprehensively understand their mechanisms of 
      action, dosage requirements, and long-term effects in different patient 
      populations.
FAU - Pires, Bruno
AU  - Pires B
AUID- ORCID: 0000-0002-4181-9130
AD  - Centro de Investigacao em Ciencias da Saude, Universidade da Beira Interior 
      (CICS-UBI), 6201-506 Covilha, Portugal.
FAU - Rosendo, Luana M
AU  - Rosendo LM
AUID- ORCID: 0000-0002-0461-8540
AD  - Centro de Investigacao em Ciencias da Saude, Universidade da Beira Interior 
      (CICS-UBI), 6201-506 Covilha, Portugal.
FAU - Brinca, Ana Teresa
AU  - Brinca AT
AUID- ORCID: 0000-0002-7172-348X
AD  - Centro de Investigacao em Ciencias da Saude, Universidade da Beira Interior 
      (CICS-UBI), 6201-506 Covilha, Portugal.
FAU - Simao, Ana Y
AU  - Simao AY
AUID- ORCID: 0000-0003-3199-1866
AD  - Centro de Investigacao em Ciencias da Saude, Universidade da Beira Interior 
      (CICS-UBI), 6201-506 Covilha, Portugal.
AD  - Laboratorio de Farmaco-Toxicologia, UBIMedical, Universidade da Beira Interior, 
      6200-000 Covilha, Portugal.
FAU - Barroso, Mario
AU  - Barroso M
AUID- ORCID: 0000-0001-8848-2734
AD  - Servico de Quimica e Toxicologia Forenses, Instituto Nacional de Medicina Legal e 
      Ciencias Forenses, Delegacao do Sul, 1150-219 Lisboa, Portugal.
FAU - Rosado, Tiago
AU  - Rosado T
AUID- ORCID: 0000-0003-0469-2895
AD  - Centro de Investigacao em Ciencias da Saude, Universidade da Beira Interior 
      (CICS-UBI), 6201-506 Covilha, Portugal.
AD  - Laboratorio de Farmaco-Toxicologia, UBIMedical, Universidade da Beira Interior, 
      6200-000 Covilha, Portugal.
AD  - Centro Academico Clinico das Beiras (CACB)-Missao de Problemas Relacionados com 
      Toxicofilias, 6200-000 Covilha, Portugal.
FAU - Gallardo, Eugenia
AU  - Gallardo E
AUID- ORCID: 0000-0002-1802-8998
AD  - Centro de Investigacao em Ciencias da Saude, Universidade da Beira Interior 
      (CICS-UBI), 6201-506 Covilha, Portugal.
AD  - Laboratorio de Farmaco-Toxicologia, UBIMedical, Universidade da Beira Interior, 
      6200-000 Covilha, Portugal.
AD  - Centro Academico Clinico das Beiras (CACB)-Missao de Problemas Relacionados com 
      Toxicofilias, 6200-000 Covilha, Portugal.
LA  - eng
GR  - UIDB/00709/2020 and UIDP/00709/2020/CICS-UBI projects UIDB/00709/2020 and 
      UIDP/00709/2020, financed by national funds through the Portuguese Foundation for 
      Science and Technology (FCT)/MCTES/
PT  - Journal Article
PT  - Review
DEP - 20231108
PL  - Switzerland
TA  - Life (Basel)
JT  - Life (Basel, Switzerland)
JID - 101580444
PMC - PMC10671856
OTO - NOTNLM
OT  - amphetamines
OT  - stimulants
OT  - therapeutic
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/25 12:44
MHDA- 2023/11/25 12:45
PMCR- 2023/11/08
CRDT- 2023/11/25 01:21
PHST- 2023/10/10 00:00 [received]
PHST- 2023/11/03 00:00 [revised]
PHST- 2023/11/06 00:00 [accepted]
PHST- 2023/11/25 12:45 [medline]
PHST- 2023/11/25 12:44 [pubmed]
PHST- 2023/11/25 01:21 [entrez]
PHST- 2023/11/08 00:00 [pmc-release]
AID - life13112180 [pii]
AID - life-13-02180 [pii]
AID - 10.3390/life13112180 [doi]
PST - epublish
SO  - Life (Basel). 2023 Nov 8;13(11):2180. doi: 10.3390/life13112180.